| Identification | Back Directory | [Name]
Butanamide, N-hydroxy-4-[3-[9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]phenoxy]- | [CAS]
1809163-24-3 | [Synonyms]
HDAC-IN-43
Butanamide, N-hydroxy-4-[3-[9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]phenoxy]- | [Molecular Formula]
C22H28N6O4 | [MOL File]
1809163-24-3.mol | [Molecular Weight]
440.5 |
| Hazard Information | Back Directory | [Uses]
HDAC-IN-43 is a potent HDAC 1/3/6 inhibitor with IC50 values of 82, 45, and 24 nM, respectively. HDAC-IN-43 is a weak PI3K/mTOR inhibitors with IC50 values of 3.6 and 3.7 μM, respectively. HDAC-IN-43 shows broad anti-proliferative activity [1]. | [IC 50]
HDAC6: 24 nM (IC50); HDAC3: 45 nM (IC50); HDAC1: 82 nM (IC50); HDAC10: 182 nM (IC50); HDAC2: 358 nM (IC50); HDAC8: 1441 nM (IC50); HDAC11: 9061 nM (IC50) | [References]
[1] Dizhong Chen, et al. Synthesis and biological evaluation of 6-phenylpurine linked hydroxamates as novel histone deacetylase inhibitors. Bioorg Chem. 2020 May;98:103724. DOI:10.1016/j.bioorg.2020.103724 |
|
|